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Since the autumn of 1996, two recombinant FSH preparaThe objective of this prospective study was to compare the tions (Gonal-F and Puregon) have successively been introduced outcome of ovarian hyperstimulation for in-vitro fertilizain IVF markets starting in Europe, and we now have experience tion (IVF) using two different preparations of recombinant of the two preparations available in Sweden for nearly 1 year.
follicle stimulating hormone (FSH). The study was based
Both preparations had undergone extensive clinical trials in on 296 consecutive IVF cycles in 1997, 199 performed collaboration with several European centres (Loumaye et al., using follitropin alpha (Gonal-F) and 97 performed using 1993; Devroey et al., 1994) , and at the time of the introduction follitropin beta (Puregon). Outcome was compared regardof the products in Sweden, it was emphasized that the two ing pregnancy rate, oestradiol and progesterone response, preparations were similar but not identical. endometrial thickness, follicle number, number of retrieved Data exist to suggest that recombinant FSH is more potent oocytes, fertilized oocytes, sperm count and sperm motility.
than the highly purified urinary FSH preparations (Out et al., There was no significant difference in outcome of stimula-1996, 1997) . Partly based on these studies, Puregon was tion. Clinical pregnancy rate was similar, 29.1% for Gonalbelieved to be somewhat more potent than Gonal-F; therefore, F and 28.1% for Puregon. There was no difference in the drug was made available in ampoules of 50, 100 and 150 IU endometrial response, oestradiol response, number of rather than the 'standard' size of 75 and 150 IU. Furthermore, smaller (12-15 mm) or larger (>15 mm) follicles, number recommended dosages were slightly lower than for Gonal-F. of oocytes retrieved, fertilized, divided and replaced, in Both preparations have been used at our clinic since the sperm counts or in sperm progressive motility. There was beginning of 1997. It was postulated that there might be a a lower follicle number in the Puregon group, but not difference between the two preparations with regard to stimulastatistically significant. The serum progesterone concentration outcome, and therefore the present analysis of stimulation tions on the day of oocyte retrieval, however, were significoutcome in 296 consecutive cycles in 1997 was performed. antly lower in the Puregon group. In conclusion, it was not possible to find significant differences in the IVF Materials and methods programme with regard to stimulation outcome between Gonal-F and Puregon. The results of this study indicate Introduction assigned either Gonal-F or Puregon based on the odd or even last digit in their date of birth (year, month, day). Characteristics of the Controlled ovarian hyperstimulation for in-vitro fertilization patients in the study are given in Table I. (IVF) using preparations containing follicle stimulating hormone (FSH) has been routinely performed since the 1980s.
Ovarian stimulation protocol
The early preparations used were urinary human menopausal All patients followed our standard long gonadotrophin-releasing gonadotrophins (HMGs) containing FSH and luteinizing hormone agonist (GnRHa)-HMG protocol for stimulation as described hormone (LH) in a 1:1 ratio (Muasher et al., 1985 ; Navot and earlier (Csemiczky et al., 1995; Fried et al., 1996) . GnRHa (Suprefact; Rosenwaks, 1988; Palermo et al., 1988; Edelstein et al., 1990;  Svenska Hoechst AB, Stockholm, Sweden) was administered as a Torok et al., 1991) . In the 1990s, highly purified urinary FSH nasal spray 6ϫ200 µg/day starting on day 21 of the menstrual preparations were introduced because of a desire to provide cycle, and was reduced to half the dose when FSH injections were drugs for s.c. injections and with a lower risk of allergic commenced. After down-regulation was verified by vaginal ultrasound scanning, 75-300 IU/day of recombinant FSH (Gonal-F; Serono reactions (Howles et al., 1994) . Expectations of future insuffi- (23) by vaginal ultrasonography using a Siemens Sonoline SI/200 in 2 37 (13) 14 (5) combination with blood samples for 17β-oestradiol assays. When an 3 1 (1) -adequate stimulation was achieved, i.e. a controlled rise in serum oestradiol and a leading follicle diameter of at least 17 mm, 10 000 IU human chorionic gonadotropin (HCG; Profasi; Serono Nordic AB, analysis was performed using Spearman correlation. Tests were Sollentuna, Sweden) was given s.c. Approximately 35 h later ovum performed with the statistical package Graphpad Prism and Statmate retrieval was performed by transvaginal ultrasound-guided follicle (Graphpad Software Inc, San Diego, CA, USA). A P-value Ͻ 0.05 aspiration. IVF, embryo transfer and pregnancy follow-up was perwas considered significant. formed as described elsewhere (Csemiczky et al., 1995) . Luteal phase support was given using 400 mg micronized progesterone as vaginal
Results
suppositories three times daily until a pregnancy test was performed and if found positive, continued 8 weeks after embryo transfer.
The characteristics of the study population are presented in Pregnancy was defined as a serum HCG concentration Ͼ10 IU/l 2 Table I . There were no significant differences between the weeks after embryo transfer and subsequently rising. Clinical pregGonal-F and Puregon groups with regard to age, reasons for nancy was defined as presence of an intrauterine fetus with regular infertility, duration of stimulation or presence of male factor. heart beats. Criteria for cycle cancellation were (i) no rise in oestradiol Regarding male factor, most of the male partners had sperm even after an increase in dose, (ii) only three or fewer follicles counts Ͼ5ϫ10 6 /ml after swim-up preparation. However, 29 approaching 17 mm diameter, (iii) high risk for developing ovarian males (15.8%) in the Gonal-F group and 17 (19.5%) in the hyperstimulation syndrome -sharp rise in oestradiol and Ͼ25 follicles.
Puregon group had sperm counts Ͻ1ϫ10 6 /ml. In 22 and 12
Hormone assays of these cases respectively, intracytoplasmic sperm injection Serum 17β-oestradiol and progesterone were assayed by the Central (ICSI) was performed. There was no difference in the use of Laboratory for Clinical Chemistry, Karolinska Sjukhuset by radio-ICSI between the two groups. For the remaining patients, immunoassay, using reagents from the Farmos Group (Oulu, Finland). regular IVF was used. Cryopreservation was performed in eight cycles (seven Gonal-F, one Puregon ) with a mean of
Statistical analysis
4.4 (three to six) preimplantation embryos. In five Gonal-F Prior to statistical analysis, data were tested for Gaussian distribution freeze cycles embryo transfer was performed, resulting in one using a normality test (the Kolmogorov-Smirnov test). Some data twin pregnancy, whereas the embryo transfer in the Puregon were found not to be normally distributed. Therefore, non-parametric freeze cycle was unsuccessful.
statistics were used for all the data. Comparisons between mean
The outcome of stimulation of the two groups is shown in values were made using the Mann-Whitney rank sum test. Although
Tables II-IV. The pregnancy rate (calculated on the number the standard errors were therefore not used for statistical comparisons, they have been appended to the mean values in the tables. Correlation of cycles where embryo transfer was performed) was not larger follicles in the Gonal-F group, but the difference was not statistically significant (P ϭ 0.06).
The ovarian response in terms of oestradiol production/ secretion is shown in Figure 1 . Oestradiol levels in the early follicular phase were slightly higher in Gonal-F than in the Puregon cases, however, the difference was not significant up to 3 days before oocyte retrieval at oocyte retrieval or at embryo transfer. Oestradiol concentrations were compared in patients becoming pregnant and those remaining non-pregnant. Neither in the Gonal-F nor in the Puregon-treated group were the oestradiol levels at oocyte retrieval or at embryo transfer significantly different in this respect.
The progesterone levels in serum at oocyte retrieval, i.e. the day after HCG, were significantly higher in the Gonal-F group compared to the Puregon group, 37.7 Ϯ 1.5 nmol/l (n ϭ 164) versus 30.3 Ϯ 1.8 nmol/l (n ϭ76 ) (P ϭ 0.005). In the patients who became pregnant, the corresponding values were 35.4 Ϯ 2.8 nmol/l (n ϭ 52, Gonal-F) versus 26.7 Ϯ 3.3 nmol/l (n ϭ 24, Puregon) (P ϭ 0.03), and in the non-pregnant patients the values were 38.7 Ϯ 1.8 nmol/l (n ϭ 112, Gonal-F) versus in progesterone concentrations were seen between the two (hatched bars). Concentrations were measured daily from 9 days before oocyte retrieval until 2 days before retrieval, on the day of groups or between pregnant and non-pregnant patients on the oocyte retrieval and on the day of embryo transfer. day of embryo transfer.
A correlation analysis regarding progesterone concentrations at oocyte retrieval revealed that in both the Gonal-F and the Puregon group, progesterone concentrations were strongly Table V . Stimulation response, number of replaced embryos and sperm quality in 271 consecutive cycles where HCG was given and where oocyte correlated with oestradiol levels from 2 days prior to oocyte retrieval was performed, using two different preparations of recombinant retrieval, on the day of oocyte retrieval and on the day of FSH. Values given as means Ϯ SEM embryo transfer (P Ͻ 0.0001). In addition, progesterone concentrations were also correlated with the number of small Gonal-F Puregon (n ϭ 184) (n ϭ 87)
follicles (12-15 mm) (P ϭ 0.03), the total number of oocytes retrieved (P ϭ 0.005) and the number of cleaved oocytes Endometrial thickness before oocyte 10.9 Ϯ 0.2 11.2 Ϯ 0.3 (P Ͻ 0.0001).
retrieval (mm)
A detailed analysis was performed regarding the total dose No significant differences were found in pregnancy rate ( Figure  2a ) or in any of the other examined parameters (Figure 2b -h) in relation to total dose between the administered preparations significantly different between the two groups, resulting in clinical pregnancy rates of 29.1 and 28.9% for Gonal-F and used for stimulation. The duration of stimulation was correlated to total dose Puregon respectively, whereas the ongoing pregnancy rates were 20.6% for both groups. The biochemical pregnancy rates within both the Gonal-F and the Puregon group, increasing with higher doses (Figure 2b) . At a total dose of ഛ1500 IU, were 34.1 and 35.0% per embryo transfer for Gonal F and Puregon respectively.
oocyte retrieval was performed at 13.4 Ϯ 0.5 days in the Gonal-F group as compared to 14.6 Ϯ 0.3 in the Puregon There was no difference between the two groups in the ovarian and endometrial response to the FSH stimulation group. At a total dose of Ͼ3000 IU, the duration of the stimulation increased to 17.3 Ϯ 0.5 and 16.5 Ϯ 0.4 days ( Table V) . The endometrial thickness before oocyte retrieval, as well as the numbers of smaller (12-15 mm) and larger respectively. The serum concentrations of oestradiol at oocyte retrieval (Ͼ15 mm) follicles, were similar. Neither were there any significant differences with regard to the number of oocytes were also correlated to the total dose in both the Gonal-F and the Puregon group, and decreased with higher doses (Figure  retrieved , fertilized, cleaved and replaced, nor in sperm counts/ sperm progressive motility. There was a higher number of 2c). At a total dose of ഛ1500 IU, oestradiol was 3808 Ϯ 283 pmol/l in the Gonal-F group as compared to 3459 Ϯ 509 301 pmol/l. The serum concentrations of progesterone at oocyte retrieval were higher in the Gonal-F group at total pmol/l in the Puregon group. The corresponding concentrations for a total dose of Ͼ3000 IU were 1928 Ϯ 212 and 1508 Ϯ doses up to 2500 IU (Figure 2d ), but not above.
The numbers of smaller follicles (12-15 mm) were related as mentioned above, neither the difference in total dose, nor the difference in follicle numbers was statistically significant. to the total dose in both groups, decreasing with higher The higher concentrations of progesterone found in the doses (Figure 2e) . At ഛ1500 IU, there were 10.2 Ϯ 1.4
Gonal-F group did not appear to have any clinically relevant follicles in the Gonal-F group as compared to 7.3 Ϯ 1.4 in effects as compared to Puregon, i.e. the pregnancy rates were the Puregon group. At Ͼ3000 IU, the corresponding numbers the same, as well as the proportion of biochemical pregnancies were 3.8 Ϯ 0.8 and 2.3 Ϯ 1.0 respectively. The numbers of and miscarriages. Elevated progesterone concentrations in the larger follicles (Ͼ15 mm) did not vary significantly with total follicular phase have been suggested to have a predictive value dose (Figure 2f) .
for the outcome of pregnancies achieved by IVF by some The numbers of retrieved and fertilized oocytes were also authors (Burns et al., 1994) , but this has been questioned by correlated to the total dose in both groups, and decreased with others (Huang, 1996) . In the present study, a difference was a higher dose (Figure 2g, h) . At ഛ1500 IU, there were 9.3 Ϯ only seen on the day of oocyte retrieval, and as discussed 1.1 and 5.4 Ϯ 0.8 oocytes respectively, in the Gonal-F group above, may be related to the number of developing follicles. as compared to 7.2 Ϯ 0.7 and 4.1 Ϯ 0.7 oocytes in the Puregon On the day of embryo transfer there was no significant group. At Ͼ3000 IU, the corresponding numbers were 5.4 Ϯ difference between the Gonal-F group and the Puregon group, 0.6 and 3.9 Ϯ 0.6 respectively in the Gonal-F group as indicating that there is no difference between the two in the compared to 5.8 Ϯ 1.1 and 2.8 Ϯ 0.8 in the Puregon group. luteal phase. The small difference observed between Gonal-F and Puregon may be related to differences in molecular composition of the Discussion two preparations. It has been shown that the clinical efficacy The present study clearly indicates that both of the recombinant of FSH principally may be related to the proportion and FSH preparations currently on the market are equally well amount of acidic isoforms and to the degree of molecular suitable for use in ovarian stimulation. Both can be selfcomplexity (Chappel, 1995) . In a recent biochemical comparadministered s.c., which is a great clinical advantage. The ison between Gonal-F and Puregon, it was shown that Gonalresults of this study reveal no significant clinical difference F is slightly more acidic than Puregon, whereas both Gonal-F between Gonal-F and Puregon regarding number of follicles and Puregon were far more similar to human urinary menostimulated, number of oocytes retrieved and fertilized or in pausal gonadotrophins (Fertinorm/Metrodin) than to highly pregnancy rate. A recent comparison between Gonal-F and purified urinary FSH (Fertinorm HP/Metrodin HP). Both Puregon on a small number of patients, 22 in each group recombinant FSH preparations, in addition, were shown to be (Brinsden et al., 1998) , is in agreement with the results more similar to human mid-cycle endogenous FSH than the presented here. The current study was designed as a prospective urinary preparations (Robertson, 1998 ; see also Recombinant randomized study in 1997, but due to the later introduction of Human FSH Product Development Group, 1998). Earlier Puregon, there was a higher number of Gonal-F cycles. Even studies on human menopausal gonadotrophin preparations from though this is a drawback, the two groups were well matched these two suppliers have also indicated differences in molecular with regard to age, body mass index and indication for composition using isoelectric focusing (Harlin et al., 1986) . treatment (see Table I ).
The analysis regarding stimulation outcome in relation to The only statistical difference found was that progesterone the total dose given revealed no difference in potency between on the day of oocyte retrieval was higher in the Gonal-F Gonal-F and Puregon. The two preparations required a similar group. A slightly higher number of follicles and higher levels stimulation length for optimal effect, 15.2 days for Gonal-F of oestradiol in the Gonal-F group were also observed, although and 16 days for Puregon (given as days from start of FSH these were not statistically significant on the day of oocyte injections until oocyte retrieval, in terms of days of FSHretrieval. The higher progesterone concentrations observed in injections this translates to 12.2 days for Gonal-F and 13 days the Gonal-F group may be related to this observation. The for Puregon). It has been claimed that recombinant FSH is correlation of progesterone concentrations on the day of oocyte more effective than highly purified urinary FSH (Bergh et al., retrieval to the oestradiol concentrations, to the number of 1997; Out, 1996; Recombinant Human FSH Product Developsmaller follicles and to the number of oocytes retrieved strongly ment Group, 1998) . Recombinant FSH in this respect may be supports this suggestion. The recruitment of a higher number more similar to the original HMG preparations. It should of follicles using Gonal-F would explain both higher oestradiol however be noted that duration of stimulation and total dose and progesterone concentrations. This is also supported by required may be dependent on the type of down-regulation findings in a recent study comparing the efficacy of 100 IU used, why direct comparisons between studies with different versus 200 IU Puregon, where it was found that the 200 IU protocols are difficult to evaluate. Even when a common group had significantly higher progesterone concentrations on protocol was used, variation between clinics was identified the day of HCG; this group also had more follicles and more as an important factor potentially contributing to observed oocytes retrieved (Out et al., 1999) . In the current study, the differences in the five-centre prospective, randomized, doubledGonal-F group received a slightly higher total dose of FSH blind clinical trial of two fixed doses of Puregon (Out et al., than the Puregon group, 2182 Ϯ 61 as compared with 2105 1999). In a previous study, HMG (Pergonal) was compared Ϯ 74, a difference of 77 IU. This difference may be related with highly purified FSH (Fertinorm-HP/Metrodin) using the same type of down-regulation used in the present study, and to the higher numbers of follicles in the Gonal-F group, but
